Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136497 | 0.75 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9379693 | 0.73 | CHRM2 (0.41) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2821568 | 0.72 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2821565 | 0.72 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3 | |
| Bromide SCHEMBL9293775 | 0.72 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL31731969 | 0.70 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL205297 | 0.70 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL668521 | 0.70 | HCAR2 (0.40) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2822867 | 0.69 | CHRM2 (0.41) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8557075 | 0.69 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | TPMT, DHFR, S1PR5 | CHRM2 2359/4885CHRM4 3366/4885CHRM1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.